NSEGeneral Updates1d ago · 30 Oct 2026, 03:20 pm
General Updates
Alkem Laboratories Limited · ALKEM
✦ AI SummaryRegulatory
Alkem Laboratories Limited has informed the Exchange about a US FDA inspection at its API manufacturing facility located at Mandva, which was concluded with no form 483 observation.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alkem Laboratories Limited has informed the Exchange about US FDA Inspection at Company s API manufacturing facility located at Mandva.
Attachments (1)
📄pdf
Download →
ALKEM_30102026152036_Closure_of_USFDA_inspection_-Mandva-signed.pdf
View document text
30th October, 2026
The Corporate Relationship Department National Stock Exchange of India Limited
BSE Limited Exchange Plaza,
Phiroze Jeejeebhoy Towers, Bandra Kurla Complex,
Dalal Street, Bandra East,
Mumbai 400 001. Mumbai 400 051.
Scrip Code: 539523 Scrip Symbol: ALKEM
Sub: US FDA Inspection at Company’s API manufacturing facility located at Mandva
Dear Sir/Madam,
This is to inform you that US FDA had conducted a inspection at the Company’s API
manufacturing facility located at Mandva from 26th October, 2026 to 30th October, 2026.
The said inspection was concluded with no form 483 observation.
Kindly take the same on record.
Sincerely,
For Alkem Laboratories Limited
Manish Narang
President- Legal, Company Secretary and Compliance Officer